Journal of Bone Research

Journal of Bone Research
Open Access

ISSN: 2572-4916

+447480721009

Dr. Qingdi Quentin Li

Dr. Qingdi Quentin Li

Dr. Qingdi Quentin Li
Senior Research Scientist, Center for Cancer Research
National Cancer Institute, USA

Biography

Q. Quentin Li is a research scientist at the National Cancer Institute, National Institutes of Health, and was an assistant professor at the Mary Babb Randolph Cancer Center, West Virginia University Robert C. Byrd Health Sciences Center. He was a guest professor/visiting professor for six reputed universities in China. He obtained an M.D. from China and worked as dermatologist at Sun Yat-Sen University School of Medicine. He also received his M.S. in Microbiology & Immunology and Ph.D. in Pharmacology and Experimental Therapeutics from the University of Maryland School of Medicine, with postdoctoral training in Molecular and Cell Biology of Cancer in Medical Oncology Branch (formerly Medicine Branch) of the Center for Cancer Research at the National Cancer Institute. He is a member of the American Association for Cancer Research. He served as principal investigator on several grants funded by the National Institutes of Health and a pharmaceutical company. He was elected to Who’s Who in Medicine and Healthcare, Who’s Who in Science and Engineering, Who’s Who in America, and Who’s Who in the World in 2002 and 2003. He serves on the Editorial Board of four journals and is a reviewer for 30 or more scientific journals and a research & development foundation. He has authored over 90 peer-reviewed research articles and reviews and presented more than 50 papers at national and international scientific meetings.

Research Interest

Quentin Li is a research interests includes: Molecular & cell biology of cancer; Photoimmunotherapy of bladder cancer; Oncopharmacology & cancer chemotherapy; New antitumor drug research & development; Natural products as novel anticancer agents; Apoptosis & cell cycle control in cancer cells; DNA repair capacity & platinum drug resistance in human carcinomas; Epigenetic modulation of DNA damage responses and DNA repair; Identification of biomarkers and epigenetic markers for diagnosis and treatment of carcinomas; Epigenetic regulation of gene expression in T cells and leukemic cells; Interface between angiogenesis and platinum sensitivity; Platinum and taxol drug resistance in lung cancer, ovarian cancer, bladder cancer, and other types of solid tumor.

Top